On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to...
On today's podcast, host Wayne Bowden joins Biorasi's Omar Ibrahim and IBM Watson Health HOPE team members Dr. Mehool Patel and Dr. Dilhan Weeraratne...
"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to...